Rigvir® for Pancreatic Cancer: Functional Principle and Survival Rates
If you’re searching for ways to beat pancreatic cancer, virotherapy may significantly help you. Virotherapy is based on using oncolytic viruses to fight certain types of cancer, and Rigvir® is the first officially recognized medicine for destroying malignant tumours.
Almost a half of a century ago a Latvia professor Aina Muceniece unveiled the power of a virus to reduce the number of cancer cells in human bodies. This virus was called Rigvir®, deriving from Riga virus. A range of research was conducted, and the results showed that one of the most common types of cancer, melanoma, is responsive to Rigvir®.
To save the necessary characteristics, Rigvir® is kept in cool temperatures
How does it work? Rigvir® is stored in vials to be used for injections. Once Rigvir® reaches your body, it finds the malignant cells and destroys them. Rigvir® travels from one cell to another eliminating only the malignant ones.
Inviolability of the healthy cells, an absence of side effects (temperature increase up to 37.5°C/99.5°F is possible) and opportunity to combine Rigvir® with radiotherapy and chemotherapy are the competitive advantages of virotherapy for pancreatic cancer.
Moreover, virotherapy is used not only to cure pancreatic cancer. There have been successful clinic trials related to:
- Rigvir for bladder cancer
- Rigvir for prostate cancer
- Rigvir for variety of sarcomas
- Rigvir for kidney cancer
- Rigvir for ovarian cancer
- Rigvir for glioblastoma
- Breast cancer etc.
Unfortunately, Rigvir® is not suitable to fight lymphoma, myeloma, and leukemia as it targets solid tumors only.
In October 2015 Melanoma Research, a specialized medical journal, published an article about Rigvir® and its potential to increase the chances to survive cancer in 4-6 times.
Georgia and Armenia recognized Rigvir® in 2015 and 2016 accordingly. However, Latvia remains the first to register and sell Rigvir® vials in 2004. Moreover, as a country of Rigvir® invention, Latvia draws attention of patients and doctors desiring to study and apply virotherapy methods.
Would you like to qualify for virotherapy in Latvia? The first thing to do is to collect your medical files based on which you will receive free eligibility assessment from virotherapists. You will be asked to provide the following medical reports so the oncologists can study your case and provide their medical opinion within 48-72 hours:
- MRI, CT
- Cytological files
- Histopathological findings
- Recent blood count (maximum of 2 weeks)
- Biochemical analysis (ALT, creatinine)
After getting the response and detailed instructions including the duration and cost of treatment, you can start packing your suitcase to visit the virotherapy clinic at the sunny beach of Jurmala, Latvia. (If it's more convenient for you to travel to Germany, please read about Rigvir in Germany.)
If you would like to know whether you or someone you know can benefit from Rigvir® therapy and how much it costs, click the button below and we'll get back to you within the next 24 hours.
List of References
Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
- “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.